BioWa, Inc. and Lonza have entered into a licensing agreement with arGEN-X BV, under which arGEN-X will have access to the companies’ POTELLIGENT CHOK1SV Cell Line Technology for the development of ARGX-110, a monoclonal antibody targeting CD70 positive tumors.
POTELLIGENT CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation POTELLIGENT Technology with Lonza’s GS Gene Expression System that includes the CHOK1SV host cell line. The technology is designed to improve the potency and efficacy of therapeutic antibodies by enhancing antibody-dependent cellular cytotoxicity (ADCC).
“The POTELLIGENT Technology has become a global standard over the last decade for the enhancement of ADCC in therapeutic antibody development, as evidenced by our parent company, Kyowa Hakko Kirin Co., Ltd. and our licensed partners,” said Yasunori Yamaguchi Ph.D., president and chief executive officer of BioWa. “We are very pleased to provide additional value to arGEN-X’s therapeutic pipeline with this extended partnership.”
“The GS System and the CHOK1SV Cell Line have proven to be key aspects of a successful mammalian expression platform. We are proud to be able to support arGEN-X in developing ARGX-110 through the granting of this license,” said Karen Fallen, vice president and head of licensing, Lonza Custom Development Services.